B cells diff erentiate to antibody-secreting plasma cells (ASCs) in vivo in response to T cell -independent (TI) antigens, generating extrafollicular ASCs that are short lived and secrete antibody of low affi nity. Responses to T cell -dependent (TD) antigens proceed with diff erent kinetics and in a specialized microenvironment, the germinal center, where T cells collaborate with their cognate B cells by providing signals that induce rapid division, isotype switching, and somatic hypermutation in the B cells. The ASCs that result from these interactions tend to be long lived and secrete antibodies of high affi nity. The T cells signal to the B cell via surface CD40 ligand (CD40L) and cytokines such as IL-4 and IL-5. In the mouse, IL-4 is both a survival factor for B cells and an inducer of isotype switching, primarily to IgG1 and IgE. In contrast, IL-5 acts to increase the likelihood of diff erentiation of conventional B cells to ASCs ( 1, 2 ) and supports B-1 cell proliferation, survival, and Ig production ( 3 -6 ) .
The intrinsic genetic program that drives the diff erentiation of ASCs is becoming clear ( 7 ) . As a prerequisite, the B cell and germinal center programs, which are actively maintained in large part by Pax5 and Bcl6, respectively, must be extinguished. These transcription factors inhibit diff erentiation by repressing genes that are required for ASC generation or function ( 8 -10 ) . Critical among them is Blimp1, a transcriptional repressor that is essential for the terminal diff erentiation of ASCs ( 11 -13 ) . Once induced, Blimp1 neutralizes Pax5-and Bcl6-mediated repression, thus enabling the expression of the plasma cell -specifi c gene program, in collaboration with other essential regulators such as IFN regulatory factor (IRF) 4 and Xbp1 ( 14 -16 ) . Recent work has revealed that the initiation of plasma cell diff erentiation is Blimp1 independent ASC diff erentiation, as well as the signaling pathways that they engage, are important but poorly understood determinants of the humoral response.
Oct2, one of the fi rst transcriptional activators recognized in B lymphocytes, was isolated as a nuclear factor that recognizes a conserved motif in the promoters and enhancers of the Ig gene loci. Although early circumstantial fi ndings suggested a role for Oct2 in the B cell -specifi c expression of Ig genes, an essential role has not been substantiated by genetic studies ( 21, 22 ) . Instead, postnatal survival and the diff erentiation and specialization of peripheral B cells depend on this factor ( 23, 24 ) . Nevertheless, serum antibody in naive oct2-null mice and their humoral immune responses are much diminished compared with normal mice. The current study was designed to uncover factors contributing to this immunodefi ciency.
As oct2 Ϫ / Ϫ mice display several abnormalities within the B cell compartment, we chose to examine their capacity to diff erentiate to ASCs under well-defi ned in vitro conditions, where even small deviations from normal could be quantitatively distinguished ( 1 ) . We found that oct2-null B cells and is accompanied by a decrease in Pax5 activity through a posttranslational mechanism that has not yet been explained ( 17 ) .
However, the extrinsic signals that initiate ASC diff erentiation are less clear. A strong signal through the BCR is thought to signal Bcl6 degradation and, thus, derepression of blimp1 ( 18 ) . Bacterial products such as LPS can drive TI ASC diff erentiation, whereas CD40L and T cell -derived cytokines signal TD ASC diff erentiation, particularly IL-4, IL-5, and IL-21 in the mouse and IL-6 and IL-10 in humans. Interestingly, recent studies suggest that TD ASC diff erentiation may require additional regulatory factors compared with TI ASC. For example, the coactivator Oct binding factor (OBF) 1, which regulates several aspects of mature B cell behavior, is selectively required for ASC diff erentiation in vitro in response to T cell stimuli and in vivo in response to vaccination with a protein antigen ( 19 ) . In another study, the Stat3 protein, which is activated by many cytokines (including IL-6 and IL-10), was shown to be required for the generation of IgG-secreting ASCs ( 20 ) . These recent fi ndings suggest that the nature of extrinsic regulators of fetal liver has allowed the behavior of oct2-null lymphoid cells to be assessed. These studies highlighted the contribution that Oct2 makes to the diff erentiation of specialized mature B cell subsets (unpublished data) ( 24 ) . Surprisingly, no evidence from studies on oct2 mutant mice supports the proposal that Oct2 regulates the transcription of Ig genes, either alone or in conjunction with its sometime partner, the coactivator OBF1/ OCA-B/Bob.1 ( 25 ) . Nevertheless, the serum of mice reconstituted with oct2 Ϫ / Ϫ lymphocytes contains signifi cantly lower levels of Ig of all isotypes than control reconstituted mice, whether naive or immunized ( 23 -25 ) .
We therefore assessed the ability of oct2-null B cells to differentiate to ASCs in vitro in response to CD40L and cytokines. These conditions were chosen for two reasons. First, we have made detailed, quantitative studies of the behavior of normal B cells under these conditions, measuring rates of cell division, isotype switching, and ASC diff erentiation ( 1 ), and we can therefore recognize deviations from normal responses. Second, oct2 Ϫ / Ϫ B cells respond poorly to other polyclonal mitogens, such as LPS and BCR cross-linking antibodies ( 23, 24, 26 ) , so these activators could not be used.
diff erentiate normally to fully functional ASCs under conditions that mimic TD conditions (CD40L plus IL-4). Only when the diff erentiation enhancing cytokine IL-5 was included did the mutant cells behave aberrantly. These studies led to the identifi cation of the inducible chain of the IL-5 receptor, IL-5R ␣ /CD125, as a B cell -specifi c Oct2 target gene, and to a model whereby IL-5 signaling directly accelerates the ASC diff erentiation program through increased expression of blimp1. Because Oct2 is required for several important responses in B cells, including BCR and Toll-like receptor (TLR) 4 signaling, several aspects of B cell diff erentiation are disturbed in vivo in its absence. Its participation in TD ASC generation is unlikely to have been revealed without the use of the quantitative in vitro analyses used in this study. 
Regulation of IL-5R ␣ expression by T cell signals
Most resting B cells express the ␤ chain but not the ␣ chain of the IL-5 receptor and therefore do not respond to the cytokine. Upon activation, IL-5R ␣ is induced, and the cells become responsive ( Fig. 2 A ) ( 27, 28 ) . We therefore examined more closely the regulation of IL-5R ␣ expression on WT and mutant B cells. Resting B cells were activated for 2 d with anti-CD40 antibodies. This treatment did not signifi cantly elevate IL-5R ␣ expression from resting cell levels ( Fig. 2 A ) , indicating that activation alone is not suffi cient for IL-5R ␣ induction. Weber et al. ( 29 ) reported that IL-4 addition enhanced IL-5R ␣ expression on LPS-treated B cells. We therefore looked for IL-5R ␣ induction in response to IL-4. This cytokine alone did not induce IL-5R ␣ , but the combination of ␣ CD40 and IL-4 was a strong inducer ( Fig. 2 A ) , and this induction required Stat6, the primary signal transducer of the IL-4R ( Fig. 2 B ) . Oct2-defi cient B cells failed to completely up-regulate IL-5R ␣ under these conditions, although expression of the receptor rose from resting cell levels ( Fig. 2 C ) . Thus, Oct2 contributes to, but does not entirely control, IL-5R ␣ levels. Despite its role as an integrator of CD40 and IL-4 signals in the context of germinal center development, the coactivator OBF1 had no infl uence on IL-5R ␣ expression under these conditions ( Fig. 2 C ) .
We found that oct2-null B cells behave indistinguishably from WT B cells in CD40L+IL-4 cultures, undergoing isotype switching to IgG1 and diff erentiating to Syndecan1 + ASCs in a cell division -linked manner ( Fig. 1 A ) . Sorted Syndecan1 + cells were ASCs, as determined by ELISPOT, and Oct2-defi cient ASCs secreted at least as much Ig as did controls ( Fig. 1 B ) .
We previously demonstrated that when IL-5 was added to CD40L+IL-4 cultures, ASC diff erentiation was enhanced. The ASCs generated in such cultures were rapidly dividing plasmablasts that were no longer able to switch isotypes ( 1 ). This IL-5 -dependent enhancement can be seen in the control cultures of Fig. 1 A but not in oct2 Ϫ / Ϫ B cell cultures ( Fig. 1 C ) . The sensitivity of B cells to IL-5 is also refl ected in the percentages of IgG1 + cells in cultures with increasing IL-5 concentrations; at high concentrations, switched cells are less frequent in control cultures because a higher proportion of cells have become ASCs, which do not switch ( 1 ) . In oct2 Ϫ / Ϫ cultures, IL-5 had no eff ect on the proportion of switched cells, an indirect consequence of the lower frequency of ASC diff erentiation ( Fig. 1 D ) . These data reveal both a new role for Oct2 in the cytokine-driven augmentation of ASC production and the absence of an essential role for Oct2 in the regulation of Ig production by preformed ASCs. ␣ CD40+IL-4. The results indicated that IL-5R ␣ is expressed even in undivided B cells ( Fig. 2 D ) . Thus, although IL-5 acts to enhance ASC generation, it is unlikely to contribute signifi cantly to the cell division dependence of this diff erentiation step.
The observation that ASC diff erentiation is cell division dependent ( 1 ) prompted us to ask whether expression of the IL-5R ␣ chain was also division linked. We purifi ed resting B cells, labeled them with the cell division tracking dye CFSE, and stained for CD125 expression after 48 h in culture with As B cells required Oct2 to respond to IL-5 in all assays that we have performed, we assessed whether the IL-5R might require Oct2 for its expression. Although the IL-5R ␤ chain was not aff ected in the mutants (not depicted), quantitative PCR analysis showed that the IL-5R ␣ chain was expressed at abnormally low levels in primary B cells from oct2 Ϫ / Ϫ mice compared with control B cells ( Fig. 3 C ) . Indeed, the loss of Oct2 had an even more dramatic eff ect on expression of this new putative target gene than was seen for the bona fi de Oct2 target, CD36 ( Fig. 3 C ) ( 34, 35 ) .
To begin to dissect the mechanism of action of Oct2 on the IL-5R ␣ gene, we made use of OM1A, a cloned oct2 Ϫ / Ϫ B lymphoma cell line, and a cloned derivative that had been transduced with a retroviral construct expressing an Oct2 -estrogen receptor (ER) fusion protein ( 36 ) . In the absence of estradiol, Oct2-ER is cytoplasmic, and induction causes the Oct2-ER protein to moved quickly and quantitatively to the nucleus (unpublished data). The cells were induced with estradiol in the presence of CHX to ask whether Oct2 could directly activate transcription of the endogenous IL-5R ␣ gene. Interestingly, in contrast to the CD36 gene, estradiol + CHX modestly increased IL-5R ␣ expression in the absence of Oct2-ER, implying that IL-5R ␣ is normally repressed by a labile factor. Induction of Oct2 dramatically enhanced both CD36 and IL-5R ␣ transcription in the absence of new protein synthesis ( Fig. 3 D ) , suggesting that Oct2 acts directly to activate the IL-5R ␣ gene.
Oct2 binds to the IL-5R ␣ gene promoter Using 5 Ј rapid amplifi cation of complementary DNA (cDNA) ends (RACE), we found that the majority of IL-5R ␣ transcripts in the spleen were initiated at or very near the A residue at position Ϫ 4870 bp from the start of translation (or 166 bp upstream of the 5 Ј end of the IL-5R ␣ reference cDNA sequence, available from GenBank/EMBL/DDBJ under accession no. NM_008370 ; Fig. 4 A ) . The adjacent sequences did not contain a classical TATA box, but a 5-bp AT-rich sequence was found at approximately position Ϫ 30 from the putative start of transcription. In their review of the features of eukaryotic promoters, Smale and Kadonaga ( 37 ) note that AT-rich sequences at approximately position Ϫ 30 can profoundly infl uence promoter strength, even if they do not resemble the TATA consensus. In addition, there is a fi ve out of seven match to the consensus initiator sequence ( 37 ) near the common 5 Ј end of IL-5 enhances blimp1/prdm1 expression We next examined the molecular consequences of IL-5 treatment on B cells. In these assays, the B cells were from a mouse expressing the GFP from the endogenous blimp1 promoter. Thus, all ASCs generated in vivo or in vitro express GFP ( 30 ) . Addition of IL-5 to CD40L+IL-4 cultures increased the number of cells expressing blimp1/GFP, and the GFP + cells were Syndecan1 + ASCs ( Fig. 2 E and not depicted) .
To assess the ability of IL-5 to directly activate transcription of the blimp1 gene, we prepared replicate cultures of WT B cells in LPS. 3 d later, cycloheximide (CHX) was added to both cultures at a concentration (50 M) that we determined would inhibit protein synthesis while preserving cell viability. 1 h later, IL-5 was added to one culture only, and cells were harvested 5 h after cytokine addition. Quantitative PCR analysis showed that LPS alone is a strong inducer of blimp1 expression, as expected ( Fig. 2 F ) . Addition of CHX did not infl uence blimp1 messenger RNA levels, but the further addition of IL-5 enhanced blimp1 expression approximately fourfold over LPS alone ( Fig. 2 F ) . Blimp1 up-regulation was observed only in the IL-5 + CHX-treated and not the IL-5 + DMSO-treated sample. Similar results were obtained in TD culture conditions, using anti-CD40+IL-4 to drive diff erentiation ( Fig. 2 F ) . These results suggest that the blimp1 gene is repressed by a labile repressor but that release from repression is alone insuffi cient to activate the gene. The addition of IL-5 rapidly up-regulates blimp1 transcription in the absence of new protein synthesis, most likely through activation and nuclear transport of its cognate signal transducer, Stat5 ( 31 ) . There are two perfect consensus Stat5 binding sites in the blimp1 promoter, at positions Ϫ 1325 and Ϫ 931 relative to the start of transcription ( 32 ) .
Oct2 regulates the IL-5R ␣ gene expression in B lymphocytes but not eosinophils
In addition to its eff ects on diff erentiation, IL-5 acts as a coactivator for B cell proliferation when in combination with anti-CD38 ( 33 ) . This response is also absent in oct2 Ϫ / Ϫ B cells ( Fig. 3 A ) . However, the proliferation of eosinophils, another IL-5 -responsive cell type, was not dependent on Oct2. Oct2 Ϫ / Ϫ fetal liver stem cells cultured in IL-5 gave rise to normal numbers of eosinophil colonies of normal size ( Fig. 3 B ) . Therefore, expression of the IL-5R is regulated diff erently in B cells and eosinophils.
independent reconstituted mouse of the indicated genotype. The percentages of Syndecan1 ϩ cells were made relative to the percentage generated without IL-5 for each sample, and the IL-5 -dependent fold increase is displayed. This was done to enable comparison between experiments, as the mice in each cohort varied somewhat in their levels of B cell reconstitution, and the staining and analysis gates used on different days also varied slightly. The percentages of Syndecan1 ϩ cells in the non -IL-5 cultures ranged from 3 to 7.6% across the eight animals assessed. the IL-5R ␣ RACE products. These features suggest that the preferred transcriptional start site for the IL-5R ␣ gene in splenocytes (of which B lymphocytes are the major cell type) lies in this region.
A search of the upstream sequence of the IL-5R ␣ gene using the ConSite transcription factor binding site search tool ( 38 ) revealed two nonconsensus octamer motifs ( Fig. 4 A ) . Two methods were used to determine whether Oct2 is able to bind directly to these sites. First, chromatin immunoprecipitation (ChIP) was performed, using chromatin isolated from control WEHI231 or Oct2-defi cient OM1A B lymphoma cell lines and a polyclonal anti-Oct2 antiserum. The results indicated that Oct2 bound specifi cally to chromatin in the IL-5R ␣ promoter in the vicinity of the two octamer motifs (5 Ј ChIP) and to the CD36 promoter, a known Oct2 target gene ( Fig. 4 B ) . Two independent experiments are shown, and the relative enrichments (using WEHI231 + preimmune serum as the reference sample) diff er between experiments because the second experiment had a lower level of nonspecifi c immunoprecipitation overall. EMSA was used to learn whether one or both of the octamer motifs were bound by Oct2. IL-5R ␣ octamer site 1 (the most 5 Ј ) was able to bind to a nuclear protein, forming a complex that had the same mobility as an Oct2 -consensus octamer DNA complex (V H octa) and that was specifi cally supershifted by a monoclonal anti-Oct2 antibody ( Fig. 4 C ) . The more 3 Ј IL-5R ␣ octamer site 2 did not exhibit specifi c binding to Oct2. Collectively, these data indicate that Oct2 binds directly to the promoter of the IL-5R ␣ gene to activate its transcription specifi cally in B cells.
Provision of an IL-5R ␣ transgene selectively rescues ASC differentiation in oct2 ؊ / ؊ B cells
We crossed the oct2 mutant mice to a transgenic mouse strain expressing the IL-5R ␣ gene constitutively in B cells ( 39 ) to determine whether enforced expression of IL-5R ␣ could rescue some aspects of the oct2 mutant phenotype. Because oct2 Ϫ / Ϫ mice do not survive postnatally, all experimental mice were generated using adoptive transfer of fetal liver stem cells into Rag1 Ϫ / Ϫ recipients. The reconstituted mice were analyzed after at least 2 mo of reconstitution. We specifi cally assessed the ability of the transgene to complement the defective ASC diff erentiation of oct2 Ϫ / Ϫ B cells identifi ed in vitro ( Fig. 1 ) . Purifi ed, resting splenic B cells from mice reconstituted with control, oct2-null or oct2-null/ IL-5R ␣ transgenic fetal liver stem cells were cultured in CD40L+IL-4 in the presence or absence of IL-5. After 4 d, cells were harvested and stained for Syndecan1 expression, and antibody in culture supernatants was measured by ELISA. IL-5 increased the proportion of Syndecan1 + cells in the control but not the oct2-defi cient cultures. The IL-5R ␣ transgene largely restored the ability of oct2 Ϫ / Ϫ cells to diff erentiate in response to IL-5 in a concentration-dependent manner, generating a higher percentage of Syndecan1 + cells and a corresponding increase in secreted Ig in the cultures ( Fig. 5 A  and not depicted) . These reconstitution studies indicate that a primary role of Oct2 in these TD cultures is to activate the IL-5R ␣ gene, enabling effi cient diff erentiation of ASCs. We also observed a lower proportion of Syndecan1 + ASCs in the spleens and bone marrow of mice reconstituted with oct2 Ϫ / Ϫ B cells expressing the blimp1/gfp reporter allele compared with controls ( Fig. 5 B and not depicted) . This may refl ect, in part, a defi ciency of ASCs that would have been generated in vivo during TD responses to environmental antigens, mediated by IL-5 through Oct2 and IL-5R ␣ .
We found that the IL-5R ␣ transgene did not convincingly rescue any of the other defects of the B cell lineage of oct2 mutant mice in vivo. For example, the proportion of B cells in the spleen remained low ( Fig. 5 B ) , and there was an abnormally high percentage of immature cells in the spleen of oct2-null mice, whether or not they bore the IL-5R ␣ transgene ( Fig. 5 C ) . Similarly, the transgene failed to rescue the marginal zone (MZ) or B-1 cell populations of the oct2 Ϫ / Ϫ mice ( Fig. 5, D and E ) . It was regularly noted that the B-1 compartment of control transgenic mice was larger than control nontransgenics, consistent with the reported activity of the transgene and the particular responsiveness of B-1 cells to IL-5 ( 6 ) . The failure of the transgene to complement these defects highlights the selective role that IL-5 and its receptor play during B cell development, and emphasizes the fact that Oct2 regulates other genes important for normal B lymphocyte development and function, such as those mediating BCR signaling ( 23 ) .
DISCUSSION
Recently, many groups have worked to elucidate the intrinsic factors that are required for the differentiation of antigenactivated B cells into ASCs ( 7 ) . These studies have identifi ed essential transcriptional regulators, such as Blimp1, Bach2, Bcl6, IRF4, Xbp-1, and Pax5, whose activities orchestrate the transition from the mature B cell and germinal center genetic programs to one dedicated to high level Ig synthesis and secretion. Less clear are the modes of action of extrinsic signals, as well as their associated downstream signaling pathways, in initiating or enhancing this important transition. In this study, we consider the T cell -derived cytokine IL-5 as one such extrinsic signal.
In the mouse B cell lineage, IL-5 seems to serve primarily as an enhancer of antibody. It supports cells of the B-1 cell lineage, which constitutively express IL-5R ␣ ( 27, 40 ) . These cells are the source of most " natural " Ig in the serum and are poised to diff erentiate very rapidly to ASCs upon activation ( 41 ) . Resting follicular B cells are unresponsive to IL-5. We show that two T cell signals, CD40L and IL-4, strongly synergize to condition splenic B cells to become IL-5 sensitive. This dramatic synergy would ensure that only those B cells activated in the context of T cell help could be accelerated toward ASC diff erentiation by IL-5. In follicular B cells, IL-5 has a clear and specifi c activity in enhancing ASC diff erentiation from follicular B cells ( Fig. 1 ) ( 1 ) . Finally, IL-5 has been shown to improve the survival of BMderived plasma cells ( 42 ) . We show that Oct2 is required for It is not yet known whether Oct2 contributes to human TD ASCs through IL-5, or another cytokine, in an analogous way to the mouse. There is less evidence for a role of IL-5 on human B lymphocytes, although actions of IL-5 on human B cells have been reported ( 45, 46 ) . Instead, IL-6 and/or IL-10 induce ASC diff erentiation of CD40L-activated human B cells in vitro ( 47 -49 ) . Both IL-6 and IL-10 signal through Stat3, as can IL-5 ( 50 ).
Our in vitro evidence ( Fig. 2 E and not depicted) suggesting that IL-5 alone is unable to up-regulate blimp1 expression in mouse B cells indicates that the blimp1 gene is insulated against untimely induction. Here, a short pulse of IL-5 was only able to stimulate blimp1 expression after 3 d of culture. At earlier time points (24 -48 h of culture), blimp1 expression was not infl uenced by IL-5 addition (unpublished data). These observations accord with those reported by Horikawa et al. ( 2 ) showing that IL-5 induces blimp1 in CD38-activated B cells slowly (over several days). These observations, the requirement for several cell divisions before ASC diff erentiation occurs in vitro ( 1 ) , and the positive eff ect that an inhibitor of protein synthesis had on blimp1 expression ( Fig. 2 ) are all consistent with the obligate loss of a blimp1 repressor over the fi rst hours and days of activation. Once the repression is released, the blimp1 gene of a plasma cell precursor B cells to be able to eff ectively " read " this T cell signal. Oct2 binds directly to the promoter of the IL-5R ␣ gene and increases its transcription in splenic B cells. We have demonstrated a dependence on Oct2 during ASC diff erentiation in vitro in response to IL-5 stimulation, as well as a specifi c improvement of diff erentiation effi ciency when IL-5R ␣ was provided to Oct2-defi cent B cells as a transgene.
Overexpression of IL-5 has been shown to signifi cantly increase antibody levels in vivo, predominantly from an expanded population of B-1 cells ( 40 ) . Conversely, IL-5R ␣ -defi cient or IL-5 -depleted mice showed impaired B-1 cell development and reduced serum IgM, IgG3 and mucosal IgA ( 6, 39, 43 ) . The IL-5R ␣ transgene used in this study supported increased percentages of peritoneal B-1 cells in control mice but no rescue of this population in the oct2 Ϫ / Ϫ mutants ( Fig. 5 E ) . Furthermore, it was not possible to rescue the serum antibody defect in oct2-defi cient animals by reconstitution with this single Oct2 target gene ( Fig. 5 F physiological roles of tissue-restricted gene regulators such as Oct2 and OBF1.
MATERIALS AND METHODS
Cell preparation and culture. All mice used in the study were on a C57BL/6 genetic background, including the blimp1-GFP reporter ( 30 ) and IL-5R ␣ transgenic mice ( 39 ) . All animal studies were approved by the Animal Ethics Committee of the Royal Melbourne Hospital Research Foundation. Splenic B cells were prepared as previously described ( 19 ) , using anti-CD45R/B220 -coupled magnetic beads (Miltenyi Biotec). For CFSE labeling experiments, Percoll gradients were included to enrich for resting cells, as previously described ( 1 ) . Soluble CD40L and recombinant IL-4 and IL-5, purifi ed from baculovirus-infected Sf9 cells (both used at 1,000 U/ml unless otherwise noted in the fi gures), and LPS (from 10 μ g/ml Escherichia coli 0111: B4; Sigma-Aldrich) were used as previously described ( 1, 19 ) . Anti-CD38 (NIM-R5) and anti-CD40 (FGK-4.5) were purifi ed from hybridomas provided by M. Howard (ChemoCentryx Inc., Mountain View, CA) and A. Rolink (University of Basel, Basel, Switzerland), and were used at 10 μ g/ml.
[ 3 H]Thymidine incorporation was used as previously described ( 23 ) to measure proliferation in vitro.
Embryonic day 18 fetal liver cells were cultured at 25,000 cells per milliliter in 1-ml cultures of Dulbecco ' s modifi ed Eagle ' s medium with 20% fetal calf serum and 0.3% agar. The reagents used to stimulate eosinophil colony formation were 0.1 ml of pokeweed mitogen -stimulated spleen-conditioned medium containing GM-CSF and IL-3, or 10 ng/ml IL-5, as a specifi c stimulus for eosinophil colony formation. Cultures were scored after 7 d. Cell counts ± SD were made on individual colonies in the stained cultures.
For the experiments in Fig. 2 F , the sensitivity of LPS-activated B cells to CHX was determined. B cells were cultured in LPS for 3 d, and then for 6 h with increasing concentrations of CHX, after which viability (using propidium iodide exclusion) and protein translational activity (using incorporation of 1 μ Ci per well of [ 35 S]-Express protein labeling mix; Perkin Elmer) were measured. At 50 μ M CHX, translation was completely inhibited, but cell viability was equivalent to control cultures treated with DMSO only (not depicted). B cells were cultured for 3 d with the stimuli shown in Fig. 2 F , CHX or DMSO were added, and IL-5 was added to selected cultures 1 h later. Cells were harvested for RNA from all cultures 5 h after cytokine addition.
The oct2 Ϫ / Ϫ B lymphoma cell line OM1A ( 36 ) was infected with a retroviral vector (pMX-pie) ( 62 ) expressing GFP and oct2 fused to the hormone binding domain of the human ER from a single transcript. Puromycin resistant clones were selected for high GFP expression, and the ␤ -estradiol -inducible nuclear translocation of the oct2-ER fusion protein was confi rmed by subcellular fractionation and Western blotting (unpublished data). For the induction experiments in Fig. 3 D , a clone of OM1A -oct2-ER was cultured with 50 μ M CHX (or DMSO as a vehicle control). 1 h later, IL-5 was added to the indicated cultures, and the cells were harvested for RNA after a further 5 h.
Flow cytometry. Anti-Syndecan1 (281-2), anti-CD125 (T21), and anti-B220 (RA3-6B2; all PE conjugated), and anti -thy-1.2 (30-H12), anti-IgM (R6-60.2), anti-IgD (11-26c.2a), and anti-CD23 (B3B4; all FITC conjugated) were purchased from BD Biosciences. Anti-CD21 was purifi ed from a hybridoma supplied by K. Inoue (Osaka University Medical School, Osaka, Japan) and biotinylated. A. Strasser (Walter and Eliza Hall Institute, Melbourne, Australia) purifi ed the NimR-5 (anti-CD38) antibody. CFSE labeling was performed as previously described ( 1 ).
ELISPOT and ELISA. In Fig. 1 B , 200 sorted Syndecan1 + cells from day 4 of a culture (CD40L+IL-4) of resting B cells were plated for ELISPOT assay, performed essentially as previously described ( 1 ) using anti-Ig -coupled horseradish peroxidase as the developing reagent. For the ELISA assay, 6,000 sorted Syndecan1 + cells were plated in medium without stimuli, and the culture supernatants were harvested 6 h later. Measurement of Ig , IgM, and IgG1 levels in culture supernatants, or Ig levels in serum, was performed as previously described ( 63 ) .
would become responsive to the positive infl uence of IL-5 signaling. Strong candidates for the blimp1 repressors are Bcl6 ( 8 ) and Bach2, which have been shown to bind directly to the blimp1 gene ( 51, 67 ) , and Pax5 ( 9, 52, 53 ) . Indeed, Horikawa et al. showed that bcl6 messenger RNA levels declined within hours of IL-5 addition in their culture system ( 2 ), and Kallies et al. showed that a reduction of Pax5 activity precedes blimp1 induction ( 17 ) .
In vivo, signals that derepress the blimp1 gene are likely to come from T cells and their products and through the BCR, as has been proposed by Niu et al. ( 18 ) . In one model, Bcl6 competes for binding on the blimp1 gene with the transcriptional activator Stat3, with which it shares a consensus DNA binding motif ( 54 ) . A strong BCR signal leads to degradation of Bcl6, vacating the DNA binding site in favor of Stat3, which is activated in response to IL-6 and other cytokines. It is intriguing to note that Stat3 binds to the same consensus DNA binding motif as Stat5 ( 55 ) . Stat5 is a major transducer of signals from the IL-5R ( 56 ) . Thus, Bcl6 and Stat5 may also compete as negative and positive regulators of blimp1 expression.
Recent work has highlighted the importance of the combined infl uences of blimp1 and IRF4 during ASC diff erentiation ( 17, 57, 58 ) . Thus a model for TD ASC diff erentiation in vivo ( Fig. 6 ) may incorporate the combined eff ects of antigen receptor signaling (to relieve Bcl6 repression) and T cell signals: a CD40 signal to up-regulate IRF4 expression through the canonical NF-B pathway and to further reduce Bcl6 expression ( 59 ) , and cytokines such as IL-5, which boost the expression of the blimp1 gene ( Fig. 2 F ) . Once blimp1 and IRF4 levels reach a critical threshold, a mutual reinforcement has been proposed ( 57, 58 ) that drives the ASC diff erentiation program forward.
Both Oct2 and OBF1 have been shown by genetic models to be entirely dispensable for Ig gene expression in B cells and plasma cells. However, these two transcription factors are required for some of the main " sensing " functions of B cells (e.g., Oct2 for LPS sensing through TLR4, and Oct2 and OBF1 for antigen signaling through the BCR and for cytokine responses; see Results; unpublished data). As a result, many aspects of peripheral B cell behavior are faulty in the mice. OBF1 Ϫ / Ϫ mice lack germinal centers and MZ B cells, and display a reduced mature B cell pool ( 60, 61 ) . Oct2-null mice also lack MZ B cells and most mature B cells, as well as the B-1 cell population (unpublished data) ( 24 ) . In the face of these many defects, it was diffi cult to discern their specifi c roles in ASC diff erentiation. Using quantitative in vitro analyses, novel modes of action for Oct2 and OBF1 have been discovered, whereby each is required for a diff erent aspect of TD terminal ASC diff erentiation (see Results) ( 19 ) . The infl uence of each factor on serum Ig is indirect and molecularly distinct, with OBF1 required for TD but not TI ASC diff erentiation, and with Oct2 enabling the IL-5 response. The latter defect was molecularly characterized and specifi cally corrected in the studies described in this paper. Such approaches strongly complement global gene expression studies to determine the oligonucleotides were labeled using [ 32 P]dATP and Klenow DNA polymerase. Oligo sequences were as follows: IL-5R ␣ octa-1, (forward) 5 Ј -GGG GTCA-CATATCAGATATCTTGCATATCAGATATC-3 Ј and (reverse) 5 Ј -TTT-GATATCTGATATGCAAGATATCTGATATGTGACCCC-3 Ј ; IL-5R ␣ octa-2, (forward) 5 Ј -CTCTGCTAGTCACTCAGCATGAAAATCCTCA-GACT-3 Ј and (reverse) 5 Ј -TTTAGTCTGAGGATTTTCATGCTGAGT-GACTAGCAGAG-3 Ј ; and V H octa, (forward) 5 Ј -CCTTGCCTCATGA-GTATGCAAATCATGTGCGACTG-3 Ј and (reverse) 5 Ј -TTTCAGTC-GCACATGATTTGCATACTCATGAGGCAAGG-3 Ј .
Fetal liver reconstitutions. Day 13 embryos were recovered, fetal livers were dissected, and cell suspensions were prepared. After genotyping, the cells of interest were transplanted into irradiated (300 Rad) Rag1 Ϫ / Ϫ recipients, as previously described ( 23 ), at a ratio of three recipients per donor liver. Reconstitution was monitored by the appearance of mature lymphocytes in peripheral blood, and only stably reconstituted mice were included in the analyses presented in this paper.
